Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 27;13(11):599-601.
doi: 10.1093/jpids/piae098.

Ad26.COV2.S COVID-19 Vaccine Safety And Immunogenicity in Adolescents 16-17 Years of Age

Javier Ruiz-Guiñazú  1 , Mathieu Le Gars  2 , Vicky Cárdenas  3 , Nathalie Vaissière  1 , Jerald Sadoff  2 , Carla Truyers  1 , Jenny Hendriks  2 , Gert Scheper  2 , A Marit de Groot  2 , Frank Struyf  1 , Hanneke Schuitemaker  2 , Macaya Douoguih  2
Affiliations

Ad26.COV2.S COVID-19 Vaccine Safety And Immunogenicity in Adolescents 16-17 Years of Age

Javier Ruiz-Guiñazú et al. J Pediatric Infect Dis Soc. .

Abstract

2.5 × 1010 vp Ad26.COV2.S elicited robust SARS-CoV-2-specific antibody responses in adolescents through 6 months, with acceptable safety and reactogenicity profiles. Compared with adults immunized with 5 × 1010 vp Ad26.COV2.S, adolescents had higher antibody levels, despite being vaccinated with a lower dose.

Keywords: Ad26.COV2.S; COVID-19; adolescents; infectious diseases; vaccine/immunization.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Solicited adverse events in (A) adolescent participants who received 2.5 × 1010 vp Ad26.COV2.S vaccine or placebo; (B) healthy adults aged 18–55 and ≥65 years who received 5 × 1010 vp Ad26.COV2.S vaccine; and (C) healthy adults aged 18–25 years who received 5 × 1010 vp Ad26.COV2.S vaccine. The number of participants reporting each grade is shown within each section of bars. Abbreviations: vp, viral particles.
See this image and copyright information in PMC

References

    1. Bos R, Rutten L, van der Lubbe JEM, et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. NPJ Vaccines 2020; 5:91. - PMC - PubMed
    1. Hardt K, Vandebosch A, Sadoff J, et al. ; ENSEMBLE2 study group. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Infect Dis 2022; 22:1703–15. - PMC - PubMed
    1. Sadoff J, Gray G, Vandebosch A, et al. ; ENSEMBLE Study Group. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med 2021; 384:2187–201. - PMC - PubMed
    1. Sadoff J, Gray G, Vandebosch A, et al. ; ENSEMBLE Study Group. Final analysis of efficacy and safety of single-dose Ad26.COV2.S. N Engl J Med 2022; 386:847–60. - PMC - PubMed
    1. Ali K, Berman G, Zhou H, et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N Engl J Med 2021; 385:2241–51. - PMC - PubMed